Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 10.19 -2.39% -0.25
IRWD closed down 2.39 percent on Tuesday, January 26, 2021, on 1.35 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Feb 11
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical IRWD trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish -2.39%
Lower Bollinger Band Walk Weakness -2.39%
Lower Bollinger Band Touch Weakness -2.39%
Oversold Stochastic Weakness -2.39%
Older End-of-Day Signals for IRWD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 18 hours ago
Outside Day about 21 hours ago
Down 2 % about 21 hours ago
Fell Below Lower Bollinger Band about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ironwood Pharmaceuticals, Inc. Description

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Gastrointestinal Therapeutic Product Cardiovascular Disease Therapeutic Products Nervous System Disorders Central Nervous System Disorders Peptides Gastroenterology Vascular Diseases Cardiovascular Diseases Macau Gastrointestinal Disease Gastrointestinal Diseases European Union Irritable Bowel Syndrome Constipation Digestive Diseases Gastrointestinal Disorders Laxatives Human Therapeutic Products Linaclotide

Is IRWD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.23
52 Week Low 7.99
Average Volume 1,316,456
200-Day Moving Average 10.45
50-Day Moving Average 11.57
20-Day Moving Average 11.16
10-Day Moving Average 10.83
Average True Range 0.39
ADX 29.23
+DI 10.79
-DI 27.17
Chandelier Exit (Long, 3 ATRs ) 10.92
Chandelier Exit (Short, 3 ATRs ) 11.29
Upper Bollinger Band 12.17
Lower Bollinger Band 10.15
Percent B (%b) 0.02
BandWidth 18.05
MACD Line -0.33
MACD Signal Line -0.19
MACD Histogram -0.1383
Fundamentals Value
Market Cap 1.63 Billion
Num Shares 160 Million
EPS 0.70
Price-to-Earnings (P/E) Ratio 14.58
Price-to-Sales 4.60
Price-to-Book 314.01
PEG Ratio -0.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.82
Resistance 3 (R3) 10.87 10.70 10.72
Resistance 2 (R2) 10.70 10.54 10.68 10.68
Resistance 1 (R1) 10.45 10.44 10.37 10.40 10.64
Pivot Point 10.28 10.28 10.24 10.26 10.28
Support 1 (S1) 10.03 10.12 9.95 9.98 9.74
Support 2 (S2) 9.86 10.02 9.84 9.70
Support 3 (S3) 9.61 9.86 9.67
Support 4 (S4) 9.56